ENVERIC BIOSCIENCES, INC. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
ENVERIC BIOSCIENCES, INC. (ENVB) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $1.98 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-31.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2022-03-31
- ENVERIC BIOSCIENCES, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2018-12-31 was $349.71K.
- ENVERIC BIOSCIENCES, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2018-09-30 was $315.51K.
- ENVERIC BIOSCIENCES, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2018-06-30 was $276.95K.
- ENVERIC BIOSCIENCES, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2018-03-31 was $297.81K.
- ENVERIC BIOSCIENCES, INC. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2020 was $1.98M.
- ENVERIC BIOSCIENCES, INC. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2018 was $1.24M, a 71.00% decline from fiscal 2017.
- ENVERIC BIOSCIENCES, INC. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2017 was $4.28M, a 193.34% increase from fiscal 2016.
- ENVERIC BIOSCIENCES, INC. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2016 was $1.46M.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 6 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 9 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month |
|---|---|---|---|---|
| 2020-12-31 | $1.98M 10-K · filed 2022-03-31 | |||
| 2018-12-31 | $349.71K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $665.22K derived: sum of 2 quarters · filed 2020-03-25 | $942.17K derived: sum of 3 quarters · filed 2020-03-25 | $1.24M 10-K · filed 2020-03-25 |
| 2018-09-30 | $315.51K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $592.46K derived: sum of 2 quarters · filed 2019-11-08 | $890.28K 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $276.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $574.77K 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | $297.81K 10-Q · filed 2019-05-14 | |||
| 2017-12-31 | $4.28M 10-K · filed 2019-03-26 | |||
| 2016-12-31 | $1.46M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |